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Abstract
Introduction: Chemical pleurodesis is an effective treatment for malignant
effusion and pneumothorax. Although this mode of therapy is less widely
accepted in treatment of patients with hepatic hydrothorax, the need for
palliative treatment in such patients encouraged us to do this work. The aim
of study was analysing the outcome of chemical pleurodesis using bovoiodine,
Vibramycin and talc slurry in treatment of hepatic hydrothorax.
Material and methods: A case series randomized study including 23 patients
with symptomatic right side hepatic hydrothorax not responding to medical
treatment and repeated thoracocentesis was conducted. From March 2007 to
March 2008, 19 men and 4 women with a mean age of 54.3 ±8.1 years (range
42-70 years) underwent medical thoracoscopies to achieve pleurodesis by
application of 3 sclerosing agents.
Results: Out of the 23 patients pleurodesis was repeated in 20 cases. Three
cases did not attend their follow-up so their responses to pleurodesis are not
known. The follow-up period of the study was 3 months. The procedure was
effective in 15 of 20 patients (75%): 7/8 cases treated with bovoiodine (87.5%),
and 4/6 cases with Vibramycin and talc slurry (66.7%) for each. There were 
4 recurrences (20%) and a single case of mortality (5%) due to hepatic coma
which can be attributed to the course of the disease. We detected minimal
morbidity during the follow-up period of 3 months.
Conclusions: The procedure appears to be indicated for these fragile patients
especially when medical therapy fails. Chemical pleurodesis deserves to be
considered as an alterative therapy in such patients.
Key words: hepatic hydrothorax, pleurodesis, chemical sclerosing agents.
Introduction
Hepatic hydrothorax is defined as a pleural effusion usually > 500 ml,
in patients with cirrhosis without cardiopulmonary disease [1]. A reasonable
estimate is that it ranges from 4% to 6%, and even up to 10% with
advanced disease [2]. In most cases (85%) hepatic hydrothorax develops
on the right side, 13% of cases occurring on the left side and 2% being
bilateral. Hepatic hydrothorax may develop even in the absence of 
ascites [3]. 
The exact mechanism of pleural effusion remains unknown, and
a number of different mechanisms have been proposed to explain it [4].
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However, several observations indicate that the
most likely cause is passage of a large amount of
ascites from the peritoneal to the pleural cavity
through diaphragmatic defects [5, 6].
Traditional treatment of hepatic hydrothorax in
a patient who fails to respond to aggressive medical
management of ascites remains problematic and
controversial. A review of the literature has revealed
that no method is ideal yet [7, 8]. This study
describes our experience in treating patients with
refractory hepatic hydrothorax by chemical
pleurodesis as an important palliative option using
3 sclerosing agents. The effect of pleurodesis will
be evaluated with special focus on morbidity and
mortality.
Material and methods
Study population
This case series randomized study consisted of
23 patients with clinical, laboratory and radiological
evidence of liver cirrhosis, portal hypertension, and
refractory right side symptomatic hepatic
hydrothorax who were admitted to the chest and
tropical departments of Cairo University Hospital
from March 2007 to March 2008. The study was
approved by the Human Ethics Committee of Cairo
University and all subjects gave written informed
consent before thoracoscopy and chemical
pleurodesis. In this study all the 23 patients had
refractory hepatic hydrothorax, i.e. multiple medical
managements in the form of sodium and fluid
restriction together with diuretic therapy and
repeated therapeutic thoracocentesis (2-5 times)
failed to control moderate to massive transudative
pleural effusions. Exclusion criteria were evidence
of hepatic encephalopathy, massive ascites and
recent or history of haematemesis. 
Chemical pleurodesis
Medical thoracoscopy was performed under local
anaesthesia on the 23 patients included in the
study. After complete evacuation of the pleural fluid,
a chest drain was introduced, followed by
pleurodesis. In talc slurry, 2 to 3 g of asbestos-free
talc were suspended in 50 ml of saline solution
(0.9%), while with Vibramycin instillation of 1 g
vibramycin in 50 ml of saline solution and in
bovoiodine 20 ml of 10% bovoiodine in 80 ml of
saline solution were used. An additional 20 ml of
1% lidocaine was added to all the sclerosing agents
and the drain was flushed with 20 ml of saline. The
drain was then clamped for 4 h after pleurodesis,
and the patient was asked to change position every
15 min to allow adequate distribution of the
sclerosing agent. Post procedure, medical therapy
including albumin, plasma infusion and diuretics
was maintained. If the trial of pleurodesis failed
another trial was done after 3-5 days according to
the rate of fluid drainage, to a maximum of 3 times.
Pleurodesis was repeated earlier in patients with
a high rate of drainage. Chest tubes were removed
when the volume collected remained < 100 ml in
24 h. Somatostatin was given to all the patients in
a dose of 25-50 µg/h, 24 h before the procedure
and continued until removal of the chest tube.
Follow-up
Serial chest radiographs were performed 2 h
after pleurodesis, on the second post-procedure day
and at subsequent follow-up visits every month for
3 months’ follow-up. The procedure was considered
successful if there was absence of pleural fluid on
the follow-up chest radiographs; any re-accumu  -
lation was regarded as a recurrence.
Statistical analysis
Quantitative data were presented as minimum,
maximum, means and standard deviation (SD)
values. Qualitative data were presented as
frequencies and percentages. Statistical analysis
was performed with SPSS (Statistical Package for
the Social Sciences Inc., Chicago, IL, USA) version
13 for Microsoft Windows.
Results
Characteristics of subjects
The 23 patients were 19 men (82.6%) and 
4 women (17.4%). Their age ranged from 42 to 70
years (mean 54.3 ±8.1 years). They all had clinical,
laboratory and radiological evidence of liver
cirrhosis, portal hypertension, and refractory right
side symptomatic hepatic hydrothorax, i.e. they had
undergone multiple medical managements that
failed to control moderate to massive pleural
effusions. All had Child Pugh B score and the
chemical analysis of their pleural effusion showed
evidence of transudative effusion. All underwent
therapeutic thoracoscopy with pleurodesis using
bovoiodine in 9 cases, Vibramycin (doxycycline) in
7 cases, and talc slurry in 7 cases. The selection of
the sclerosing agent to be used was randomized.
During the study period, 3 patients did not attend
their follow-up visits so their response to chemical
pleurodesis is not known. These 3 cases were 1 case
from each of the 3 sclerosing agents used. The rest
of the 20 patients were followed up for 3 months.
Using the same agent, a second retrial of
pleurodesis was done in 16 cases, while it was
repeated 3 times in 4 cases (Table I).
Outcome of chemical pleurodesis
The outcome of the present work revealed that
chemical pleurodesis was effective in treatment of
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hepatic hydrothorax in 15/20 patients (75%); they
were 7/8 cases (87.5%) treated with bovoiodine, 4/6
cases (66.7%) with Vibramycin and 4/6 cases
(66.7%) with talc slurry. However, a single case
treated with talc slurry died of hepatocellular
insufficiency (5%) after 14 days following the
procedure; this patient failed to respond to
thoracocentesis repeated 5 times and also needed
pleurodesis to be repeated 3 times due to a high
rate of chest tube fluid drainage. In addition,
recurrence of pleural effusion occurred in 4 cases
(20%); they were 2 cases (50%) with encysted
effusion and another 2 cases (50%) with minimal
right side pleural effusion. Cases with pleurodesis
repeated 3 times showed more possibility of
recurrence and complications (Table II).
No. of followed up cases = 20 Povo-iodine  Vibramycin Talc slurry
Frequency %F requency %F requency %
No 1 12.5 0 0 0 0
Ascites Mild 3 37.5 2 33.3 2 33.3
Moderate 4 50 4 66.7 4 66.7
2 times 1 12.5 0 0 0 0
Previous 3 times 5 62.5 4 66.7 3 50
thoracocentesis 4 times 2 25 2 33.3 2 33.3
5 times 0 0 0 0 1 16.7
Number of 1 time 1 12.5 1 16.7 0 0
pleurodesis 2  times 7 87.5 6 75 3 50
sessions 3 times 0 0 1 16.7 3 50
Recurrence
Yes 1 12.5 2 33.3 2 33.3
No 7 87.5 4 66.7 4 66.7
Complications
Yes 6 75 4 66.7 5 83.3
No 2 25 2 33.3 1 16.7
Severity of  Moderate 2 25 1 16.7 3 50
pleural effusion Massive 6 75 5 83.3 3 50
Table I. Frequency, percentages and results of the 3 pleurodesis materials 
No. of followed up cases = 20 Recurrence No recurrence
Frequency %F requency %
Gender Male 5 100 11 73.3
Female 0 0 4 26.7
2 times 0 0 1 6.7
Previous 3 times 4 80 8 53.3
thoracocentesis 4 times 0 0 6 40
5 times 1 20 0 0
Number 1 time 0 0 2 13.3
of pleurodesis 2 times 2 40 12 80
sessions 3 times 3 60 1 6.7
Complications Yes 5 100 8 53.3
No 0 0 7 46.7
Severity of  Moderate 0 0 6 40
pleural effusion Massive 5 100 9 60
Table II. Frequency and percentages in cases with and without recurrence
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The time needed to remove the chest tube
ranged from 4 to 17 days with a mean of 9.8 ±2.3
days (in bovoiodine the range was 5-9 days with
a mean of 8.1 ±2 days, in Vibramycin the range was
6-15 days with a mean of 9.4 ±4.3 days and in talc
slurry the range was 4-17 days with a mean of 10.3
±3.6 days). Post-procedure hospital stay ranged
from 5 to 18 days.
Early post-procedure results
Post-procedure results showed that 7 out of the
22 cases reported absence of any complications and
were not associated with recurrence of hepatic
hydrothorax. The remaining cases (15 patients)
showed early and mostly minimal and limited
morbidity. There were 4/22 patients (18.2%) who
suffered from surgical emphysema, 2 patients
(9.1%) with minimal left side pleural effusion which
disappeared spontaneously after a few days, 
2 patients (9.1%) with superficial wound infection,
1 patient (4.5%) with mild thoracic pain, another
single patient (4.5%) who complained of failure of
the lung to expand immediately after the procedure
and was treated by negative suction with complete
lung expansion, and a single patient (4.5%) who
developed pre-hepatic coma 4 days after the
procedure, cured by medical therapy and associated
with no recurrence of hepatic hydrothorax.
Late post-procedure results
However, during the follow-up period 2 out of 
19 patients (10.5%) developed late complications.
A patient treated with bovoiodine suffered from
tense ascites 2 months after the procedure (3 l 
were tapped) but with no associated recurrence of
hepatic hydrothorax. The second patient treated
with talc slurry developed tense ascites and hepatic
coma at the end of the follow-up period (3 months),
recovered with medical therapy and was associated
with recurrence of encysted right side pleural
effusion. There were no reported episodes of
respiratory distress syndrome, pneumonitis or
empyema in our cases (Table III).
Discussion
Despite numerous reports describing clinical
features, pathogenesis and treatment for hepatic
hydrothorax, the optimal or standard therapy has
not been established [8]. The term refractory
hepatic hydrothorax is used when medical
treatment with salt restriction and diuretics is
ineffective, as prolonged diuretic treatment may
result in depletion of the intravascular volume and
impaired renal function. Medical therapy has proved
to be effective in just one third of the reported
patients, but the effect has been chiefly temporary.
Many authors also consider that clinical
management of hepatic hydrothorax is usually
difficult and ineffective and can result in
deterioration of the clinical status [2, 5, 8].
In contrast to ascites, which becomes massive
(< 10 l) while presenting mild symptoms in most
patients, relatively small volumes of fluid (< 1 l)
within the chest cavity cause significant symptoms
and occasionally need urgent rapid removal [9].
Although thoracocentesis is the most effective
method for rapid relief of dyspnoea secondary to
massive pleural effusion associated with hepatic
hydrothorax, it carries the risk of substantial protein
depletion without preventing fluid re-accumulation,
especially if repeated thoracocentesis is required
[7]. Pleural drainage by chest tube thoracotomy can
be very dangerous in patients with massive ascites
and pleural effusion. Runyon et al. [10] reported 
2 deaths resulting from associated massive protein
and electrolyte depletion. Also prolonged drainage
through the chest tube may cause renal failure,
impaired immunological functions and iatrogenic
infection as common sequelae [11].
Out of the 20 cases that have been followed up
during this work we used Vibramycin in 6 cases,
with no recurrence in 4 cases (66.7%). The reported
adverse effects are pain and fever with tetracycline
and pain with doxycycline [12]. In our work the
number of patients was small. Pain and fever were
not reported with the use of Vibramycin. However,
recurrence occurred in 2 patients; 1 suffered from
encysted effusion and the other from minimal right
side pleural effusion. Also, surgical emphysema, left
side pleural effusion and hepatic precoma were
each found in a single case.
In our study we selected asbestos-free talc slurry
to be used in 6 patients to avoid the claims
associated with the hazards of asbestos. We
reported no recurrence in 4 patients (66.7%). The
reported complications with talc pleurodesis include
fever, chest pain, empyema, incomplete expansion
of the lung, pneumonia, wound infection [7, 13-16]
and ARDS [17]. In our cases recurrence occurred in
a single case and complications in the form of chest
pain, surgical emphysema, left mild pleural effusion,
tense ascites and hepatic coma were each noticed
in 1 patient. Also, the only mortality in our work was
in a patient treated with talc slurry; it occurred 
14 days after the procedure due to rapid increase
of bilirubin and creatinine followed by hepatic coma
and death, and this can be attributable to the
course of the disease since the patient’s medical
status necessitated thoracocentesis 5 times before
our procedure.
We used bovoiodine in 8 cases with complete
control of the effusion in 7 cases (87.5%). Recur  -
rence in the form of encysted pleural effusion 
was noted in 1 patient (12.5%). There were
complications in the form of surgical emphysema
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in 2 patients (25%), wound infection in 2 patients
(25%), failure of the lung to expand which was
treated by negative suction with complete
expansion of the lung in 1 case (12.5%) and tense
ascites in another single case (12.5%), but there was
no pleuritic pain or hypotension seen in any of our
patients treated with bovoiodine, although these 
2 complications were the most reported in the
literature [18, 19]. The argument about the use of
iodopovidone because of these 2 complications can
be explained by the fact that the use of any
effective pleural irritant, including talc [20], can and
will produce intense pleuritic pain and a vasovagal
reaction if analgesia and anaesthesia are
inadequate, and the control of pain should be
individualized.
We used somatostatin in all of our patients to
reduce the drainage volume and shorten the
duration of chest tube removal. Somatostatin
reduces splanchnic and hepatic blood flow as well
as the portosystemic pressure gradient. Therefore,
we used it in our patient instead of TIPS, as in
contrast to TIPS, somatostatin has few, mostly
minor side effects [21, 22]. The only drawback is that
it is expensive. Our data revealed that using the 
3 sclerosing agents there was no recurrence in 
15 patients (75%) (bovoiodine 87.5%, Vibramycin
and talc slurry 66.7% each) and the rates of
recurrence and complications of the 3 sclerosing
agents used were almost comparable.
In conclusion, in our case series, we used 3 scle  -
rosing agents with a convenient outcome and
minimal complications. The medical decision in such
patients should be individualized and the balance
between treating hepatic hydrothorax and the
deterioration of the hepatic condition and ascites
should be weighed.
References
1. Xiol X, Guardiola J. Hepatic hydrothorax. Curr Opn Pulm
Med 1998; 4: 239-42.
2.  Albals WM, Salem AJ, Solomon DA, et al. Hepatic
hydrothorax: cause and management. Arch Intern Med
1991; 151: 2383-8 (Abstract).
3. Algiakrishnan K, Patel PJ. Left sided hepatic hydrothorax
with ascites. Int J Clin Pract 1999; 53: 225-6.
4. Strauss RM, Martin LG, Kaufman SL, et al. Transjugular
intrahepatic portal systemic shunt for the management
of symptomatic cirrhotic hydrothorax. Am J Gastroenterol
1994; 94: 1520-2.
5. Mouroux J, Perrin C, Venissac N, et al. Management of
pleural effusion of cirrhotic origin. Chest 1996; 109: 
1093-6.
6. Zenda T, Miyamoto S, Murata S, et al. Detection of
diaphragmatic defect as the cause of severe hepatic
hydrothorax with magnetic resonance imaging. Am 
J Gastroenterol 1998; 93: 2288-9. 
7.  Milanez de Campos JR, Filho LA, Webre EC, et al.
Thoracoscopy and talc poudrage in the management of
hepatic hydrothorax. Chest 2000; 118: 13-7.
T
a
b
l
e
 
I
I
I
.
 
C
h
a
r
a
c
t
e
r
i
s
t
i
c
s
 
a
n
d
 
o
u
t
c
o
m
e
 
o
f
 
o
u
r
 
c
a
s
e
 
s
e
r
i
e
s
 
–
 
c
o
n
t
N
o
.
 
A
g
e
S
e
x
A
s
c
i
t
e
s
P
l
e
u
r
a
l
 
e
f
f
u
s
i
o
n
 
P
r
e
v
i
o
u
s
 
S
c
l
e
r
o
s
i
n
g
 
a
g
e
n
t
 
N
o
.
 
L
e
n
g
t
h
 
C
o
m
p
l
i
c
a
t
i
o
n
s
F
o
l
l
o
w
-
u
p
/
3
 
m
o
n
t
h
s
o
f
 
c
a
s
e
s
 
[
y
e
a
r
]
t
h
o
r
a
c
o
c
e
n
t
e
s
i
s
o
f
 
s
e
s
s
i
o
n
s
o
f
 
s
t
a
y
1
6
4
5
M
M
o
d
e
r
a
t
e
R
t
 
M
a
s
s
i
v
e
3
V
i
b
r
a
m
y
c
i
n
2
1
3
*
S
u
r
g
i
c
a
l
 
e
m
p
h
y
s
e
m
a
F
o
l
l
o
w
-
u
p
 
o
f
 
p
a
t
i
e
n
t
 
f
a
i
l
e
d
*
M
i
n
i
m
a
l
 
l
e
f
t
 
p
l
e
u
r
a
l
 
e
f
f
u
s
i
o
n
1
7
5
0
F
M
o
d
e
r
a
t
e
R
t
 
M
a
s
s
i
v
e
3
V
i
b
r
a
m
y
c
i
n
2
8
_
N
o
 
r
e
c
u
r
r
e
n
c
e
1
8
5
4
M
M
o
d
e
r
a
t
e
R
t
 
M
o
d
e
r
a
t
e
3
T
a
l
c
2
1
4
S
u
r
g
i
c
a
l
 
e
m
p
h
y
s
e
m
a
N
o
 
r
e
c
u
r
r
e
n
c
e
1
9
4
5
M
M
o
d
e
r
a
t
e
R
t
 
M
a
s
s
i
v
e
4
T
a
l
c
3
1
5
_
N
o
 
r
e
c
u
r
r
e
n
c
e
2
0
5
2
M
M
o
d
e
r
a
t
e
R
t
 
M
o
d
e
r
a
t
e
3
B
o
v
o
i
o
d
i
n
e
2
9
S
u
r
g
i
c
a
l
 
e
m
p
h
y
s
e
m
a
N
o
 
r
e
c
u
r
r
e
n
c
e
2
1
5
3
M
M
o
d
e
r
a
t
e
R
t
 
M
a
s
s
i
v
e
3
B
o
v
o
i
o
d
i
n
e
2
1
1
_
F
o
l
l
o
w
-
u
p
 
o
f
 
p
a
t
i
e
n
t
 
f
a
i
l
e
d
2
2
4
2
M
M
o
d
e
r
a
t
e
R
t
 
M
a
s
s
i
v
e
3
V
i
b
r
a
m
y
c
i
n
3
1
8
*
T
e
n
s
e
 
a
s
c
i
t
e
s
R
e
c
u
r
r
e
n
c
e
 
w
i
t
h
 
*
H
e
p
a
t
i
c
 
c
o
m
a
 
3
 
m
o
n
t
h
s
 
l
a
t
e
r
e
n
c
y
s
t
e
d
 
e
f
f
u
s
i
o
n
2
3
4
8
M
M
i
l
d
R
t
 
M
o
d
e
r
a
t
e
4
T
a
l
c
2
8
L
e
f
t
 
m
i
n
i
m
a
l
 
p
l
e
u
r
a
l
 
e
f
f
u
s
i
o
n
 
N
o
 
r
e
c
u
r
r
e
n
c
e
d
i
s
a
p
p
e
a
r
e
d
 
a
f
t
e
r
 
t
u
b
e
 
r
e
m
o
v
a
l
Chemical pleurodesis in hepatic hydrothorax342 Arch Med Sci 3, June / 2010
8. Cardenas A, Kelleher T, Chopra S. Review article: hepatic
hydrothorax. Aliment Pharmacol Ther 2004; 20: 271-9.
9. Kiafar C, Gilani N. Hepatic hydrothorax: current concepts
of pathophysiology and treatment options. Ann Hept
2008; 7: 313-20.
10. Runyon BA, Greenblatt M, Ring MH. Hepatic hydrothorax
is a relative contraindication to chest tube insertion. Am
J Gastroenterol 1986; 81: 566-7.
11. Borchardt J, Smirnov A, Metchnik L, et al. Treating hepatic
hydrothorax. BMJ 2003; 326: 751-2.
12. Richard W, Light MD. Pleurodesis: what agent should be
used? J Pneumol 2003; 29: 23-7.
13. Vargas FS, Milanez JR, Filomeno LT, et al. Intrapleural talc
for the prevention of recurrent in benign or undiagnosed
pleural effusions. Chest 1994; 106: 1771-5.
14. Glazer M, Berkman N, Lafair JS, et al. Successful talc slurry
pleurodesis in patients with nonmalignant pleural
effusion. Chest 2000; 117: 1404-9.
15. Yim AB, Izzat MB. Talc slurry versus talc insufflation
revisited. Ann Thorac Surg 1997; 64: 285-5.
16. Yim  AP,  Chan AT, Lee TW, et al. Thoracoscopic talc
insufflation versus talc slurry for symptomatic malignant
pleural effusion. Ann Thorac Surg 1996; 62: 1655-8.
17. Light RW. Talc should not be used for pleurodesis. Am Rev
Respir Crit Care Med 2000; 162: 2024-6.
18. Morales-Gomez J, Téllez-Becerra JL, Martínez-Ormen ~o JE.
Pleurodesis conyodopovidona en el derrame pleural
neoplsico. Rev Int Nal Enf Resp Mex 1993; 6: 71-4.
19. Olivares-Torres CA, Laniado-Laborín R, Chavez-Garcia C,
et al. Iodopovidone pleurodesis for recurrent pleural
effusions. Chest 2002; 122: 581-3.
20. Brant A, Eaton T. Serious complications with talc slurry
pleurodesis. Respirology 2001; 6: 181-5.
21.  Nevens F. Resource analysis of somatostatin in the
treatment of bleeding esophageal varices. Digestion 1999;
60 (Suppl 3): 35-7.
22. Patel NH, Chalasani N, Jindal RM. Current status of
transjugular intrahepatic portosystemic shunts. Postgrad
Med J 1998; 74: 716-20.
Nariman Helmy, Yosri Akl, Safy Kaddah, Hamed Abd El Hafiz, Hisham El Makhzangy